{"id":"W1565820605","doi":"10.1158/1538-7445.sabcs14-s3-01","title":"Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":166,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Oncology; Internal medicine; Docetaxel; Carboplatin; Metastatic breast cancer; Breast cancer; Taxane; Clinical endpoint; Triple-negative breast cancer; Progression-free survival; Chemotherapy; Anthracycline; Chemotherapy regimen; Randomized controlled trial; Cancer; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001620304,0.001768619,0.002134526,0.0003800008,0.000515881,0.001392266,0.00114882,0.00183101,0.01317034],"category_scores_gemma":[0.001414073,0.000518885,0.001642701,0.0004333284,0.001363927,0.0008959805,0.0004007381,0.004472909,0.001536316],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001089836,"about_ca_system_score_gemma":0.002167875,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001508205,"about_ca_topic_score_gemma":0.003718462,"domain_scores_codex":[0.9995149,0.0002790852,0.00002401655,0.00007321914,0.00003541798,0.0000733488],"domain_scores_gemma":[0.9990121,0.0001900864,0.0001991036,0.00005189488,0.00005387076,0.0004929301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9833639,0.003539294,0.0004594733,0.0004152491,0.0003793669,0.0000397158,0.00003166662,0.0002627034,0.002385489,0.0001439931,0.002079374,0.006899917],"study_design_scores_gemma":[0.9632488,0.03466655,0.000654188,0.00002277771,0.0001999574,0.00002992669,0.00001160928,0.0002400169,0.0002583107,0.00009661318,0.0005633101,0.000007925714],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9692955,0.004412976,0.000714132,0.003019976,0.00112236,0.01045417,0.005008508,0.0002347249,0.005737635],"genre_scores_gemma":[0.9586794,0.002930216,0.002310817,0.003372712,0.0008972661,0.01178752,0.00621159,0.00008090546,0.01372951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01317034,"threshold_uncertainty_score":0.04405916,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07511545520705774,"score_gpt":0.3992765637296873,"score_spread":0.3241611085226295,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}